Oxolinic acid (Synonyms: NSC 110364, Urinox) |
| Catalog No.GC14107 |
quinolone antibiotic that inhibits bacterial DNA gyrase
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14698-29-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 4.3 μM for dopamine uptake
Oxolinic acid is a quinolone antibiotic inhibiting bacterial DNA gyrase.
DNA gyrase, an enzyme within the class of topoisomerase, relieves strain while double-stranded DNA is being unwound by helicase.
In vitro: Previous study found that both inhibitors of DNA gyrase of oxolinic acid and coumermycin A1 could block the DNA synthesis in E. coli. Moreover, the rate of bacterial DNA synthesis first rapidly declined but then increased gradually at low concentrations of oxolinic acid. In varoius DNA mutants, oxolinic acid was able to cause a rapid decline, followed by a slow decrease in synthesis rate of DNA [1].
In vivo: Animal study showed that the i.p. injection of oxolinic acid in mice could induce a dose dependent increase in locomotor activity, and such stimulation culminated at the 32 mg/kg dose and was smaller for higher doses at 64-128 mg/kg. When compared with haloperidol (D2 dopamine receptor antagonist) at increasing doses (50-100-200 mg/kg), the stimulant locomotor effect of oxolinic acid at 32 mg/kg was not reversed significantly. In addition, oxolinic acid at 32 mg/kg did not reverse the reserpine caused akinesia and even opposed the reversion that was induced by dexamphetamine [2].
Clinical trial: Oxolinic acid is an antibiotic developed in Japan in the 1970s. Oral dose at 12–20 mg/kg is administered for 5-10 days (https://en.wikipedia.org/wiki/Oxolinic_acid).
References:
[1] E C Engle,S H Manes, and K Drlica. Differential effects of antibiotics inhibiting gyrase. J Bacteriol. 1982 Jan; 149(1): 92–98.
[2] Garcia de Mateos-Verchere J,Vaugeois JM,Naudin B,Costentin J. Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor. Eur Neuropsychopharmacol. 1998 Dec;8(4):255-9.
| Cas No. | 14698-29-4 | SDF | |
| Synonyms | NSC 110364, Urinox | ||
| Chemical Name | 5-ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid | ||
| Canonical SMILES | CCN1C=C(C(O)=O)C(C2=CC(OCO3)=C3C=C21)=O | ||
| Formula | C13H11NO5 | M.Wt | 261.23 |
| Solubility | 0.5 M NaOH: 50 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.828 mL | 19.1402 mL | 38.2804 mL |
| 5 mM | 0.7656 mL | 3.828 mL | 7.6561 mL |
| 10 mM | 0.3828 mL | 1.914 mL | 3.828 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *